Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
Eur J Drug Metab Pharmacokinet August 28, 2026 DOI: 10.1007/s13318-026-01033-x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or computational modeling paper Peer reviewed |
|---|---|
| Topics | Depression Psilocybin |
| Key points | Argues that a physiologically based pharmacokinetic/pharmacodynamic model can simulate psilocybin and psilocin exposure and receptor occupancy, offering a tool to optimize dosing for treatment-resistant depression and inform clinical trial design. |
Abstract
Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.